Background Extracellular matrix degradation is regulated mainly by matrixmetalloproteinases (MMPs). MMP-3 can degrade many components of the extracellular matrix and an increase in serum MMP-3 concentration has been proposed as a synovial derived marker of inflammation.
Objectives To determine matrix metalloproteinase-3 (MMP-3) serum levels in anti Scl 70 positive patients with systemic sclerosis (SSc) and to study clinical significance and the relationship between MMP-3 and pulmonary and joint involvement
Methods Forty-seven anti-Scl 70 antibodies positive patients with systemic sclerosis (43 female, 4 male) and 50 healthy controls were included in the study. All SSc patients underwent standard assessment, including laboratory tests, physical examination with joint assessment, chest X-ray and pulmonary functional tests, including diffusion capacity for carbon monoxide (DLco) and forced vital capacity (FVC). Levels of MMP-3 were measured with specific ELISA kit (Aeskulisa DF) with normal range between 18-60 ng/ml for female and 24-120ng/ml for male.
Results SSc patients had significantly higher MMP-3 concentration compared to healthy donors 122.64±188.40 vs. 57.4±46.79, p<0.001. Twenty-two (46.8%) SSs pts had increased MMP-3 levels above normal range and those had more frequently pulmonary fibrosis (p<0.001) and arthritis (p<0.001). Patients with increased levels of MMP-3 had significantly more frequently reduction in DLco <75% predicted (p<0.001).
Conclusions In 47 patient with systemic sclerosis and anti-Scl 70 positive antibodies, high levels of MMP-3 significantly positively correlate with pulmonary fibrosis, DLCo < 75% predicted and joint involvement (arthritis).
Disclosure of Interest None Declared
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.